F. Hoffmann-La Roche Ltd: Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6 ...

Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group ...
MarketScreener

Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Waters, Quest Diagnostics Collaborate to Expand Access to At-Home HPV Screening for Cervical Cancer MT Oct. 20 Waters Corporation And Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringin ...
ainvest

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit Therapeutics SMMT is working to expand ivonescimab’s growth potential beyond non-small cell lung cancer (NSCLC), its ...
MarketScreener

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF ...

Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of ...